GRI Bio (GRI) Capital Expenditures (2020 - 2023)

GRI Bio (GRI) posted quarterly Capital Expenditures of $8000.0 for Q1 2023, up 166.67% quarter-over-quarter from $3000.0 in Q4 2022.

GRI Bio (GRI) Capital Expenditures (2020 - 2023) Analysis & Trends

GRI Bio's Capital Expenditures history runs 3 years deep, the most recent figure standing at $8000.0 for Q1 2023.

In Q1 2023, Capital Expenditures changed N/A year-over-year to $8000.0; the TTM figure through Dec 2023 stood at $8000.0 (up 166.67% YoY), while the FY2025 annual figure was $3000.0, changed N/A from the prior year.
Capital Expenditures for Q1 2023 stood at $8000.0, up from $3000.0 in the prior quarter.
The five-year high for Capital Expenditures was $8000.0 in Q1 2023, with the low at $2000.0 in Q1 2020.
The 3-year median for Capital Expenditures is $3000.0 (2022), against an average of $4333.3.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	GRI Bio	3.07 Mn	3.07 Mn	-	-

Download Data